New Paradigms in the Treatment of head & neck Cancers
Like most cancer types, treatment options for head and neck are evolving to include novel treatment approaches. Patients with head and neck region are now benefitting from advances in surgical applications, chemotherapy, and radiation therapy, resulting in increased survival and quality of life for many.
As the sixth most common cancer type, head and neck cancer represents about 6 percent of solid tumors. There are an estimated 55,000 new cases of head and neck cancer in the United States a year, including more than 1,200 new head and neck cancer patients in Arizona. Unfortunately, many patients present with advanced-stage or late-stage disease, so the sooner we know the better the outcome. Learn the risk factors for this cancer type and the evolving treatment options available for head and neck cancers.
Session participants will learn about:
• Cancer types in the head and neck region
• Impact of HPV and other risk factors
• New treatment paradigms, surgical and non-surgical options for head and neck cancers
• Tips for educating your staff about risk factors, diagnosis and treatment
About our speaker:
Aidnag Diaz, MD,
Medical Director of Radiation Medicine
The University of Arizona Cancer Center at Dignity Health St. Joseph’s Hospital and Medical Center
Aidnag Diaz, MD, is a radiation oncologist and the Medical Director of Radiation Medicine at The University of Arizona Cancer Center at Dignity Health St. Joseph’s Hospital and Medical Center. He is board certified in radiation oncology with expertise and special interest in stereotactic radiosurgery. His clinical expertise includes treating adult and pediatric patients with sarcoma, leukemia, lymphoma, central nervous system tumors and head and neck cancer. Dr. Diaz received his medical degree from Columbia University College of Physicians and Surgeons in New York and completed his training in radiation oncology at the University of California, San Francisco. He is a member of the American Society for Radiation Oncology, the Children’s Oncology Group, the Society for Immunotherapy of Cancer, and the NRG.
For more information, contact Sherry Haskins at: